Q1 2025 Legend Biotech Corp Earnings Call Transcript
Key Points
- Legend Biotech Corp (LEGN) reported a 135% year-over-year increase in net trade sales for CARVYKTI, reaching approximately $369 million.
- The company has treated over 6,000 patients with CARVYKTI, marking it as the strongest CAR-T launch to date.
- Legend Biotech Corp (LEGN) anticipates achieving operational break-even for CARVYKTI by the end of 2025 and company-wide profitability in 2026.
- The company has a strong cash position of approximately $1 billion, which supports its long-term growth and innovation strategies.
- Legend Biotech Corp (LEGN) is expanding its manufacturing capacity with facilities in Belgium and New Jersey, aiming to meet increasing global demand.
- The company reported a net loss of $101 million for the first quarter, with an adjusted net loss of $27 million after excluding non-core items.
- There are concerns about the price differential between the US and ex-US markets for CARVYKTI, which could impact global sales strategies.
- The company faces challenges in penetrating the community setting for CARVYKTI, with some investors questioning the demand and growth potential.
- Legend Biotech Corp (LEGN) is still working on reducing manufacturing turnaround times and improving efficiency, despite current progress.
- The company is navigating regulatory challenges, including the need for FDA approval for capacity expansions and potential impacts from new leadership at CDER.
Good day and thank you for standing by. Welcome to the Legend Biotech first-quarter 2025 earnings call. (Operator Instructions)
Please be advised that today's conference is being recorded. I'd like to hand the conference over to your first speaker today, Caroline Paul, Associate Director of Investor Relations. Please go ahead.
Good morning. This is Caroline Paul, Associate Director of Investor Relations at Legend Biotech. Thank you for joining our conference call today to review our first quarter of 2025 performance. Prior to this call, we issued a press release announcing our financial results for the quarter. You can find the press release on our IR website at legendbiotech.com.
Joining me on today's call are Ying Huang, the company's Chief Executive Officer; Alan Bash, the company's President of CARVYKTI; and Jessie Yeung, the company's Interim Chief Financial Officer. Following the prepared remarks, we will open up the call for Q&A. We have our President
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
